Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
Katie Zomorodi, Dan Chen, Lawrence Lee, et al.
The Journal of Clinical Pharmacology (2019) Vol. 59, Iss. 8, pp. 1120-1129
Open Access | Times Cited: 19

Showing 19 citing articles:

Recently Approved and Upcoming Treatments for Narcolepsy
Michael J. Thorpy
CNS Drugs (2020) Vol. 34, Iss. 1, pp. 9-27
Open Access | Times Cited: 97
Update on Persistent Excessive Daytime Sleepiness in OSA
Sogol Javaheri, Shahrokh Javaheri
CHEST Journal (2020) Vol. 158, Iss. 2, pp. 776-786
Closed Access | Times Cited: 91
Navigating the intersection of mental health and kidney health: a systematic review of antidepressant safety in renal impairment
Hooria Sarwar, Muhammad Zeshan, Najeeb Hussain, et al.
Discover Mental Health (2025) Vol. 5, Iss. 1
Open Access
Prescribing in Hepatic and Renal Impairment

(2025), pp. 753-786
Closed Access
Solriamfetol: First Global Approval
Anthony Markham
Drugs (2019) Vol. 79, Iss. 7, pp. 785-790
Closed Access | Times Cited: 16
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Junyi Yang, Junfa Gao
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 8, pp. 723-728
Closed Access | Times Cited: 15
First fluorescence method for monitoring the anti-doping stimulant drug solriamfetol in plasma and urine: A pharmacokinetic study in volunteers’ urine with greenness, whiteness, and blueness assessments
Medhat M. Kamel, Hend Z. Yamani, Lobna A. Hussein, et al.
Microchemical Journal (2024), pp. 111930-111930
Closed Access | Times Cited: 1
Detailed Structural Examination, Quantum Mechanical Studies of the Aromatic Compound Solarimfetol and Formation of Inclusion Compound with Cucurbituril
T. Pooventhiran, Cheriet Mouna, Utsab Bhattacharyya, et al.
Polycyclic aromatic compounds (2021) Vol. 42, Iss. 8, pp. 5443-5455
Closed Access | Times Cited: 10
Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea
Sheridan M. Hoy
CNS Drugs (2023) Vol. 37, Iss. 11, pp. 1009-1020
Closed Access | Times Cited: 2
Single‐Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC‐122) in Subjects With Mild, Moderate, or Severe Renal Impairment
Yan Li, Kimberly MacGorman, Liangang Liu, et al.
Clinical Pharmacology in Drug Development (2019) Vol. 9, Iss. 7, pp. 785-796
Closed Access | Times Cited: 5
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
Katie Zomorodi, Dan Chen, Lawrence Lee, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 4, pp. 404-413
Open Access | Times Cited: 5
Solriamfetol for the Management of Excessive Daytime Sleepiness
Megan C Cuomo, Amy Sheehan, Joe K Jordan
Journal of Pharmacy Practice (2021) Vol. 35, Iss. 6, pp. 963-970
Closed Access | Times Cited: 5
Pregnancy and Breastfeeding

(2021), pp. 679-721
Closed Access | Times Cited: 4
A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness.
Mitchell C. Fuller, Samuel W. Carlson, Haley Pysick, et al.
PubMed (2024) Vol. 54, Iss. 1, pp. 65-86
Closed Access
Solriamfetol in excessive daytime sleepiness: a profile of its use
Emma D. Deeks, Young‐A Heo
Drugs & Therapy Perspectives (2020) Vol. 36, Iss. 5, pp. 173-180
Closed Access | Times Cited: 3
Hepatic and Renal Impairment

(2021), pp. 723-754
Closed Access | Times Cited: 1
Solriamfetol and m-chlorophenylpiperazine cause false positive amphetamine results on urine drug screening
A.R. Rackow, Claire E. Knezevic
Journal of Analytical Toxicology (2023) Vol. 48, Iss. 2, pp. 126-129
Closed Access
Review of Select Sleep Medicine Pharmacology: Treatments of Hypersomnias and Parasomnia
Kimberly Johnson, Meghna P. Mansukhani, Bhanu Prakash Kolla
Elsevier eBooks (2021), pp. 179-199
Closed Access
Page 1

Scroll to top